Press Release

Biomapas, a leading provider of clinical research, pharmacovigilance (PV), regulatory affairs (RA), medical information (MI), and quality assurance (QA) services across Europe, is pleased to announce that, as of October 16th, Carbyne Equity Partners has signed to acquire strategic partnership in UAB Biomapas. This partnership between the existing shareholders and new investors marks a pivotal moment in the company’s growth journey and ensures continued growth as Biomapas builds on its 20-year legacy.

Future Outlook: Growth, Stability, and Global Expansion

With Carbyne Equity Partners on board, Biomapas is well-positioned to accelerate its global expansion and enhance its services. The company’s strategy will focus on strengthening its core services, exploring new market opportunities, and exploiting identified M&A opportunities to further drive growth. This includes developing innovative and technology-driven solutions that enable differentiated, efficient clinical development, pharmacovigilance, regulatory affairs, medical information, and quality assurance services. By continuing to partner with our clients, we help them achieve their goals with industry-leading services.

All current operations, commitments, and agreements will continue unaffected, ensuring business continuity for clients, partners, and employees alike. The executive team remains unchanged, ensuring a steady course for the company’s future.

Biomapas: A History of Excellence and a Future of Opportunity

Co-founded by the Sveikata family, Biomapas has seen steady growth since its inception, becoming a trusted name in the life sciences industry. For two decades, the company has provided comprehensive clinical research, pharmacovigilance (PV), medical information (MI), regulatory affairs (RA), and quality assurance (QA) services to clients across Europe and beyond. Under the leadership of the co-founding Sveikata family and the strong executive team led by CEO Jan Filakovsky, Biomapas has built a reputation for reliability, innovation, and excellent customer relationships.

Biomapas Chairman of the Board Audrius Sveikata expressed his confidence in the partnership:

“For Biomapas, this investment represents the next chapter in our continued growth. By joining forces with Carbyne, we will be able to further expand our service offerings and strengthen our operations globally. This partnership solidifies our future and reaffirms our commitment to our clients and employees.”

CEO Jan Filakovsky added:

“We are excited to begin this new chapter in Biomapas’ journey. Our strategy remains focused on delivering tailored, efficient, and competitive services while continuing to expand our global presence. With Carbyne’s support, we will be able to further invest in our operations and drive growth, all while maintaining the core values and operational excellence that define Biomapas.”

Carbyne Equity Partners: A Partner for Growth and Innovation

Carbyne Equity Partners is a leading European private equity firm with a focus on R&D driven sectors, including healthcare, nutrition, and agricultural technology. Backed by a globally operating and family-owned German company in the life science sector.

As Carbyne Equity Partners’ Managing Partner, Alexander Winterling, commented:

“At Carbyne, we see significant potential in Biomapas’ ability to continue expanding globally while strengthening its core services. We are looking forward to working closely with the Chairman, CEO and the Executive Team to pursue shared goals.

The transaction was advised by Stifel, with M&A advisory led by Alan Selby. Legal and tax advisory services were provided by Walless, represented by Dovile Burgiene, Domas Sileika, and Mindaugas Lukas. Carbyne Equity Partners was advised by TGS Baltic, represented by Marius Matonis and Indrė Valickaitė-Liatukė, while VINC, represented by Thomas Kern, served as the M&A advisor.